Company

Product

Description

Indication

Status

Genentech, of South San Francisco, a unit of the Roche Group

Tecentriq (atezolizumab)

Monoclonal antibody targeting PD-L1

First-line extensive-stage small-cell lung cancer

FDA accepted the supplemental BLA and granted a priority review; decision expected by March 18, 2019

Innovent Biologics Inc., of Suzhou, China

IBI-101

Anti-OX40 monoclonal antibody

Advanced solid tumors

FDA approved IND

Intrabio Inc., of Oxford, U.K.

IB-1000s

Modified amino-acid analogues/esters

Spinocerebellar ataxias

European Commission granted orphan medicinal drug designation

Recordati SpA, of Milan

REC-0559

Low-molecular-weight non-peptidic nerve growth factor mimetic

Neurotrophic keratitis

FDA granted orphan drug designation


Notes

For more information about individual companies and/or products, see Cortellis.